The FDA has penciled-in a meeting for this quarter with Sarepta Therapeutics Inc. regarding phase I/II champ golodirsen (SRP-4053) for Duchenne muscular dystrophy (DMD) patients amenable to skipping exon 53. Investors will be watching eagerly for word from the discussion, which should take the measure of relations between U.S. gatekeepers' neurology division and the Cambridge, Mass.-based company, after what H.C. Wainwright analyst Debjit Chattopadhyay noted was a "thorny," patient-driven approval process for Exondys 51 (eteplirsen).